Free Trial

Bruker Q2 2024 Earnings Report

Bruker logo
$60.07 +3.19 (+5.61%)
As of 01/21/2025 04:00 PM Eastern

Bruker EPS Results

Actual EPS
$0.52
Consensus EPS
$0.52
Beat/Miss
Met Expectations
One Year Ago EPS
$0.50

Bruker Revenue Results

Actual Revenue
$800.70 million
Expected Revenue
$799.44 million
Beat/Miss
Beat by +$1.26 million
YoY Revenue Growth
+17.40%

Bruker Announcement Details

Quarter
Q2 2024
Time
Before Market Opens

Conference Call Resources

Conference Call Audio

Slide Deck

Bruker Earnings Headlines

Guggenheim Reiterates "Buy" Rating for Bruker (NASDAQ:BRKR)
Bruker Corporation Pivots To Capitalize Its Growing TAM
Stunning Trump Manhattan Project Now Underway
Just as I predicted, President Trump announced his #1 move during his first 100 days... His allies are calling it Trump’s Manhattan Project.
Bruker’s Strategic Immunity to Export Controls Justifies Buy Rating
Guggenheim Sticks to Their Buy Rating for Bruker (BRKR)
See More Bruker Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bruker? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bruker and other key companies, straight to your email.

About Bruker

Bruker (NASDAQ:BRKR), together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.

View Bruker Profile

More Earnings Resources from MarketBeat